Skip to main content
. 2014 Jan 10;4(1):e173. doi: 10.1038/bcj.2013.71

Figure 2.

Figure 2

Outcome of 290 intensively treated CN-AML patients aged younger than 65 years with respect to BAALC expression. The median expression level was used to dichotomize the total patient cohort into low (black) and high (gray) BAALC expressers. (a) Overall survival; at 3 years: 46.2 vs 71.1%, P=0.002, (b) event-free survival; at 3 years: 31.2 vs 47.4%, P=0.006, (c) overall survival censored at the day of allogeneic SCT; at 3 years: 48.6 vs 76.1%, P=0.002.